Home › Compare › LNTEF vs ABBV
LNTEF yields 4.03% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, LNTEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LNTEF + ABBV for your $10,000?
LINTEC Corporation develops, manufactures, and sells adhesive-related products in Japan and internationally. It operates through three segments: Printing and Industrial Materials Products, Electronic and Optical Products, and Paper and Converted Products. The Printing and Industrial Materials Products segment offers adhesive products for seals and labels, labeling machines, automobile-use adhesive products, and industrial-use adhesive tapes; window, marking, and automotive films; barcode label supplies and printers, digital label printing machines, films for outdoor signs and advertising, and interior finishing mounting films. The Electronic and Optical Products segment provides semiconductor-related adhesive tapes and equipment, multilayer ceramic capacitor related tapes, and optical display-related adhesive products. The Paper and Converted Products segment offers color papers for envelopes, colored construction papers, special function papers, high-grade printing papers, high-grade papers for paper products, release papers for adhesive products, release films for optical-related products, casting papers for synthetic leather, and casting papers for carbon fiber composite materials. The company was formerly known as FSK Corporation and changed its name to LINTEC Corporation in April 1990. The company was founded in 1927 and is headquartered in Tokyo, Japan.
Full LNTEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.